# Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

> **NCT00533117** · PHASE4 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 91 (actual)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** Fluoxetine
- **BEHAVIORAL:** Dialectical Behavior Therapy
- **BEHAVIORAL:** Supportive psychotherapy

## Key facts

- **NCT ID:** NCT00533117
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2008-01
- **Final completion:** 2012-12
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533117, "Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00533117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*